Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M.

Hum Mol Genet. 2006 Jan 15;15(2):223-32. Epub 2005 Dec 1.

PMID:
16321986
2.

Contribution of GTPase activity to LRRK2-associated Parkinson disease.

Tsika E, Moore DJ.

Small GTPases. 2013 Jul-Sep;4(3):164-70. doi: 10.4161/sgtp.25130. Epub 2013 Jun 10. Review.

3.

Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.

Greggio E.

Biochem Soc Trans. 2012 Oct;40(5):1058-62. Review.

PMID:
22988865
4.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

5.

LRRK2 in Parkinson's disease: protein domains and functional insights.

Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA.

Trends Neurosci. 2006 May;29(5):286-93. Epub 2006 Apr 17. Review.

PMID:
16616379
6.

Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.

Lu YW, Tan EK.

J Neurosci Res. 2008 Jul;86(9):1895-901. doi: 10.1002/jnr.21656. Review.

PMID:
18338801
7.

A trojan horse for Parkinson's disease.

Hu Y, Tong Y.

Sci Signal. 2010 Apr 6;3(116):pe13. doi: 10.1126/scisignal.3116pe13. Review.

PMID:
20371768
8.

LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Xiong Y, Dawson VL, Dawson TM.

Biochem Soc Trans. 2012 Oct;40(5):1074-9. Review.

9.

The GTPase function of LRRK2.

Taymans JM.

Biochem Soc Trans. 2012 Oct;40(5):1063-9. Review.

PMID:
22988866
10.

Clinical features of LRRK2 parkinsonism.

Haugarvoll K, Wszolek ZK.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Review.

PMID:
20082991
11.

Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).

Mills RD, Mulhern TD, Liu F, Culvenor JG, Cheng HC.

Hum Mutat. 2014 Apr;35(4):395-412. doi: 10.1002/humu.22515. Epub 2014 Feb 24. Review.

PMID:
24470158
12.

Leucine-rich repeat kinase 2: relevance to Parkinson's disease.

Guo L, Wang W, Chen SG.

Int J Biochem Cell Biol. 2006;38(9):1469-75. Epub 2006 Mar 2. Review.

PMID:
16600664
13.

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Greggio E, Cookson MR.

ASN Neuro. 2009 Apr 14;1(1). pii: e00002. doi: 10.1042/AN20090007. Review.

14.

The unconventional G-protein cycle of LRRK2 and Roco proteins.

Terheyden S, Nederveen-Schippers LM, Kortholt A.

Biochem Soc Trans. 2016 Dec 15;44(6):1611-1616. Review.

PMID:
27913669
15.

Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.

Gómez-Suaga P, Fdez E, Fernández B, Martínez-Salvador M, Blanca Ramírez M, Madero-Pérez J, Rivero-Ríos P, Fuentes JM, Hilfiker S.

Neuropharmacology. 2014 Oct;85:45-56. doi: 10.1016/j.neuropharm.2014.05.020. Epub 2014 May 24. Review.

PMID:
24863040
16.

The biology and pathobiology of LRRK2: implications for Parkinson's disease.

Moore DJ.

Parkinsonism Relat Disord. 2008;14 Suppl 2:S92-8. doi: 10.1016/j.parkreldis.2008.04.010. Epub 2008 Jul 7. Review.

PMID:
18602856
17.

[Advance of the study on LRRK2 gene in Parkinson's disease].

Zhang Y, Chen S.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):657-9. Review. Chinese.

PMID:
19065525
18.

Phosphorylation of LRRK2: from kinase to substrate.

Lobbestael E, Baekelandt V, Taymans JM.

Biochem Soc Trans. 2012 Oct;40(5):1102-10. Review.

PMID:
22988873
19.

Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Rudenko IN, Chia R, Cookson MR.

BMC Med. 2012 Feb 23;10:20. doi: 10.1186/1741-7015-10-20. Review.

20.

Leucine-rich repeat kinase 2 for beginners: six key questions.

Kett LR, Dauer WT.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a009407. doi: 10.1101/cshperspect.a009407. Review.

Supplemental Content

Support Center